The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
n/a | n/a | 19 | 18 |
Growth
|
n/a | n/a | 71 | 77 |
Safety
|
n/a | n/a | 10 | 51 |
Sentiment
|
n/a | n/a | 58 | 58 |
|
n/a | n/a | 20 | 44 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
n/a | n/a | 100 | 87 |
Opinions Change
|
n/a | n/a | 50 | 50 |
Pro Holdings
|
n/a | n/a | 49 | 54 |
Market Pulse
|
n/a | n/a | 21 | 23 |
Sentiment
|
n/a | n/a | 58 | 58 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
n/a | n/a | 19 | 18 |
Growth
|
n/a | n/a | 71 | 77 |
|
n/a | n/a | 10 | 51 |
Combined
|
n/a | n/a | 8 | 45 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
n/a | n/a | 83 | 94 |
Price vs. Earnings (P/E)
|
n/a | n/a | 48 | 19 |
Price vs. Book (P/B)
|
n/a | n/a | 3 | 38 |
Dividend Yield
|
n/a | n/a | 1 | 1 |
Value
|
n/a | n/a | 19 | 18 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
n/a | n/a | 98 | 100 |
Profit Growth
|
n/a | n/a | 14 | 21 |
Capital Growth
|
n/a | n/a | 47 | 96 |
Stock Returns
|
n/a | n/a | 74 | 28 |
Growth
|
n/a | n/a | 71 | 77 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
n/a | n/a | 14 | 93 |
Refinancing
|
n/a | n/a | 31 | 50 |
Liquidity
|
n/a | n/a | 17 | 1 |
|
n/a | n/a | 10 | 51 |
Discover high‑ranked alternatives to Calliditas Therapeutics and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.